secwatch.observer — SEC 8-K summary
======================================

Issuer:     Altimmune, Inc. (ALT)
CIK:        0001326190
Form:       8-K
Filed at:   2026-07-28T11:04:40+00:00
Accession:  0001326190-26-000044
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Altimmune reports positive Phase 2 RECLAIM trial of pemvidutide in alcohol use disorder
--------------------------------------------------------------------------------

- Primary endpoint met: reduction in heavy drinking days/week vs placebo (LS mean diff -1.45, p=0.0014).
- 64.4% of pemvidutide patients achieved 2-level reduction in WHO Risk Drinking Level vs 34.8% placebo (p=0.0049).
- Zero heavy drinking days in 42.2% of pemvidutide patients vs 17.4% placebo (p=0.0066).
- Placebo-adjusted body weight reduction of 9.1% at 24 weeks (p<0.0001); no plateauing observed.
- Company plans to request End-of-Phase 2 meeting with FDA based on these results.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1326190/000132619026000044/0001326190-26-000044-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1326190/000132619026000044/alt-20260728x8k.htm
  HTML page:      https://secwatch.observer/filing/0001326190-26-000044

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer